Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

JURA Bio

Request full access

Creating a novel therapeutic platform of cell-based therapies against autoimmune diseases

Somerville, United StatesFounded 2017Biotech & Life Sciences

About JURA Bio

JURA Bio, Inc. is pioneering the development of novel CAR T cell therapies aimed at combating autoimmune diseases, which affect over 20 million Americans. Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to significant health issues. JURA Bio's innovative therapeutic platform focuses on targeting and neutralizing these pathogenic immune cells, thereby interrupting the damaging cascade of events triggered by the immune system's malfunction.

The company operates in the biopharmaceutical sector, specifically within the niche of cellular medicine. Its primary clients include healthcare providers, research institutions, and potentially patients suffering from autoimmune conditions. JURA Bio's business model revolves around the research, development, and commercialization of its proprietary CAR T cell therapies. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of its therapeutic products once they receive regulatory approval.

JURA Bio's approach is disruptive, leveraging the concept of immune synapses to precisely target and neutralize harmful cells. This method represents a significant advancement in the treatment of autoimmune diseases, offering hope for more effective and targeted therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
13
Open positions
None listed
Dealroom signal
67.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Sep 2023 $16M $64M Fontus Capital ↗
SPINOUT✓Other financing Jan 2017 $0 — Harvard University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

JURA Bio website traffic

Latest recorded traffic for JURA Bio is 890 monthly website visits, up 53.4% over the last three months. JURA Bio's team declined 7.1% over the past year.

Latest monthly visits890 3-month web change+53.4% 1-year team growth-7.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

JURA Bio in the Somerville ecosystem

Live from Dealroom

The JURA Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Fontus Capital

Other known investors2 additional known investors

  • Harvard University
  • Greentown Labs
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States70%
🇨🇭 Switzerland20%
🇳🇴 Norway10%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about JURA Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See JURA Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.